Key Takeaways
- Margins normalized, not collapsed: Standalone EBITDA margins settled at 17–18%, right on pre-COVID levels, after the “bonus period” of 39–40% unwound. Management frames this as a return to normal, not a crisis.
- Volumes hit by end-market de-growth: A 22% volume drop flowed from the Pharma API and Agro slump, which touches 55–60% of the product basket. Raw material supply shocks at SABIC and GC Glycol added to the drag.
- The subsidiary story is mixed: Balaji Specialty Chemicals lifted utilization to ~72% and management believes it hit its ₹180 crore PAT guide, but raw material accessibility remains the bottleneck and kept it from the 75–80% target.
- A capex cycle is loading, funded internally: Three plants (N-Butylamines, Methylamine, Dimethyl Ether) are lined up for H2 FY24 through FY24-end, with ₹250–300 crore of internal accruals earmarked for spending this year and next.
- What to watch next quarter: Whether the Pharma API pickup management sees in the last 2–3 weeks converts to orders, how quickly the last high-cost NMP inventory clears, and any news on the Maharashtra land application for the subsidiary.
The Margin Reset: From Bonus to Baseline
- The COVID-era super-cycle is over: EBITDA margins hit 39–40% during the pandemic, a period management now calls a “bonus” that cannot be taken as standard. The current 17–18% standalone margin is actually slightly above the 16–17% pre-COVID baseline.
- Realization decline is an industry pass-through: Finished product prices fell over four quarters because raw material prices fell, not because of competitive pressure. Management calls this an industry-wide phenomenon.
- High-cost inventory nearly flushed: Only one raw material (for NMP) still sits at elevated cost and will be exhausted by the first week of next month. After that, real-time inventory reflects current prices, which should lift margins.
- The path back up is gradual: Management expects 5–7% margin improvement year-on-year from here, with another similar step the following year. The 10–15 percentage-point gap to peak margins will not close quickly.
- Sustainable margin anchors: Standalone sustainable margin pegged at 22%; consolidated at 25–26%. These are the numbers management wants investors to model, not the COVID highs.
D Ram Reddy: “I just want to clarify if you remember my earlier interviews I was telling that last 4 quarters, everybody in the country like Chemical Intermediate and Specialty Chemical API Pharma, we enjoyed some bonus period, bonus in the sense pre-COVID suppose before COVID if you have done some EBITDAs 20% - 22%, during this period we have done 39% - 40% EBITDAs and we cannot take that as a standard.”
Volume De-Growth: Pharma API and Raw Material Shocks
- Pharma API drove the 22% volume drop: 55–60% of the product basket serves Pharma API end-users, and that sector de-grew globally. DMF specifically did not do well, while DMA remained in full demand, so much so that the company cannot allocate DMA to its own DMF plant.
- Raw material supply broke from two directions: SABIC and Thailand’s GC Glycol both had unexpected major shutdowns, creating short supply. SABIC restarted at the end of last month; the Thailand plant is expected back next month. The company covered from other markets for two months.
- DMF is turning, slowly: DMF is now picking up after problems from high raw material costs and dumping from outside. A new DMA plant under construction (by end of this financial year) will free up DMA for DMF production.
- Pharma pickup evidence is anecdotal but recent: Lifting of raw materials has speeded up in the last 2–3 weeks; customers have given projections. Management anticipates gradual improvement in coming months.
- Receivables tightened proactively: A 36% drop in receivables reflects both lower sales and faster recovery. Industry-wide, credit terms were cut from 120 days to 90 days, and some bad customers were rejected.
Subsidiary: Utilization Up, Raw Materials the Binding Constraint
- Utilization improved but missed the target: Balaji Specialty Chemicals reached ~72% capacity utilization, up from 56%, but fell short of the 75–80% target because of a 4–5 week raw material problem.
- PAT guide believed met: On price realization, management believes the subsidiary achieved the guided PAT of ₹180 crores despite the volume shortfall.
- Raw material accessibility is the recurring risk: Management flagged this as the major challenge and the condition for a quick ramp-up in subsequent quarters.
- Debottlenecking in progress, in installments: Part of the debottlenecking is done; remaining shutdowns are being executed in small windows because the market situation does not allow closing the plant for more than weekdays.
- Capacity doubling under consideration: If demand warrants, the subsidiary can double EDA capacity. Current utilization is at 80–90% and imports still supply 50% of the market. A call may come in 2–3 months.
- New chemistry incoming: The subsidiary recently acquired Sodium cyanide technology, with several new products planned on that line. Management cannot disclose details yet due to restrictions but expects news in 1–2 months.
- Land expansion pending: An application for ~100 acres of new land in Maharashtra has been submitted; a response is expected in 1–2 weeks.
New Plants: The FY24–FY25 Capacity Wave
- DMC and Propylene glycol are now shipping: These plants started up 6–7 months ago but real dispatches only began last month. Stocks are exhausted, the plant has restarted, and good off-take was seen. REACH registration obtained for Europe; ISO tanks already dispatched to customers there.
- Utilization ramp expected: Management expects 40–50% utilization now, rising to over 70–80% by year-end.
- N-Butylamines plant: Commissioning expected in H2 FY24 (September–October 2023). By year-end, operating at 40–50%; next year ramping to 70–75%.
- Methylamine plant: Commissioning expected around March 2024.
- Dimethyl ether plant: Commissioning by end of FY24. Targeting the aerosol market and commercial/industrial fuel as an LPG replacement. In correspondence with NITI Aayog; exact commencement date promised next quarter.
- Acetonitrile plant delayed: Previously guided for September 2023, now pushed to next year. Management cites poor ACN market conditions and says other products are more exciting. The existing 9,000-ton ACN plant is not running because import and cost prices are both ₹150, making production loss-making. New technology is being developed; pilot plant is done.
- DMAHCL and DMF plants: To come after Acetonitrile and DME; parallel execution.
- DMC expansion on hold: An additional 50,000-ton DMC plant is subject to lithium battery manufacturers starting production. 5–6 companies are in the pipeline but none have started. Management is cautious due to government restrictions on subsidiary incentives.
- All funded internally: Current year expected accruals above ₹250–300 crores; spending the same amount this year and next.
D Ram Reddy: “We expect in the coming years these existing will grow with the 8% to 10% of the volumes and new plants immediately starting it should go first year about to 30% - 40% and the next year onwards it should go to 70% to 80%.”
Competitive Positioning and Pushback
- Management claims relative outperformance: On a consolidated basis, management argues they are doing much better than peers. For Ethylamine, they are selling and retaining market share.
- ACN competitive gap not directly addressed: When asked about Alkyl Amines’ 30,000-ton ACN capacity and claimed edge from absorbed capital costs, management deflected by arguing their own Methyl and Ethylamine capital costs are also absorbed, so the logic should apply equally. They did not explain why their ACN plant is idle while a competitor is expanding.
- Sequential growth divergence with Alkyl Amines: An analyst noted Alkyl Amines showed sequential revenue growth while Balaji saw a QoQ decline. Management said they do not know the competitor’s product mix in detail and redirected to consolidated numbers.
- Subsidiary vs Diamines & Chemicals comparison: An analyst asked why the subsidiary underperformed vs Diamines & Chemicals, which has a similar portfolio and did well. Management argued the competitor is doing distillation, not manufacturing, making the comparison invalid.
- Subsidiary IPO and growth numbers declined: Management cited legal restrictions in refusing to share growth projections for the next 3–4 years.
D Ram Reddy: “If that is the case, my all Methyl, Ethyl everything is capital cost is absorbed, I am zero today, but still I am fighting with them.”
Governance and Leadership Changes
- Board reorganized due to regulatory limits: Independent directors completed 10-year terms (SEBI guidelines bar independence beyond 10 years) and 1–2 directors crossed age 75. All were replaced at once due to timing coincidence. Four new independent directors were inducted.
- CFO role split between entities: Mr. Hemant Reddy Gaddam resigned as Whole-Time Director and CFO of Balaji Amines to focus on the subsidiary as CFO. Mr. Ande Srinivas Reddy (Whole-Time Director) took additional charge as CFO of Balaji Amines. Management frames this as dividing responsibilities as both companies grow.
- CFO tenure question not fully answered: An analyst asked about the CFO appointment tenure ending March 2026 and whether it related to regulation. Management gave a general explanation about the director moving to the subsidiary but did not directly address the tenure question.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume growth | Existing products to grow 8–10% annually; new plants at 30–40% utilization year one, 70–80% year two | FY24 and beyond |
| Standalone volume target | Double current volume to 180,000–190,000 tons | By 2026 |
| Margin improvement | 5–7% year-on-year improvement from current levels | FY24 |
| N-Butylamines plant commissioning | Start in H2 FY24; 40–50% utilization by year-end | September–October 2023 |
| Methylamine plant commissioning | Plant completion | March 2024 |
| Dimethyl ether plant commissioning | Commissioning; exact date next quarter | By end of FY24 |
| Acetonitrile plant (new technology) | After DME; pilot plant done, going for main plant | Next year (FY25) |
| DMAHCL and DMF plants | After ACN and DME; parallel execution | After next year (FY26) |
| DMC and Propylene glycol utilization | Reach 40–50% now; over 70–80% by year-end | FY24 |
| Subsidiary EDA capacity doubling | Decision on doubling if demand warrants | Call in 2–3 months |
| Subsidiary land application | ~100 acres in Maharashtra; response expected | 1–2 weeks |
| CAPEX funding | ₹250–300 crores spent this year and next, all from internal accruals | FY24 and FY25 |
| High-cost NMP raw material exhaustion | Last high-cost inventory cleared | First week of next month |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Consolidated revenue | ₹477 cr, vs ₹785 cr in Q4 FY22 |
| Standalone revenue | ₹351 cr, vs ₹625 cr in Q4 FY22 |
| Consolidated EBITDA | ₹99 cr, vs ₹201 cr in Q4 FY22 |
| Consolidated EBITDA margin | 21%, vs 26% in Q4 FY22 |
| Standalone EBITDA margin | 17%, vs 21% in Q4 FY22 |
| Consolidated PAT | ₹55 cr, vs ₹131 cr in Q4 FY22 |
| Consolidated PAT margin | 12%, vs 17% in Q4 FY22 |
| Consolidated diluted EPS | ₹14.63, vs ₹33.56 in Q4 FY22 |
| Consolidated sales volume | 25,505 MT, vs 33,780 MT in Q4 FY22 |
| Subsidiary sales volume | 4,916 MT, vs 4,903 MT in Q4 FY22 |
| Subsidiary capacity utilization | ~72% in FY23, vs 56% in FY22 |
| Standalone EBITDA margin target (sustainable) | 22% |
| Consolidated EBITDA margin target (sustainable) | 26-27% |
| FY24 volume growth outlook | 10% |
| FY24 margin improvement outlook | 5-7% improvement from current levels |
| FY24 CAPEX plan | ₹250-300 cr, funded through internal accruals |